<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01774604</url>
  </required_header>
  <id_info>
    <org_study_id>CPHS#23749</org_study_id>
    <nct_id>NCT01774604</nct_id>
  </id_info>
  <brief_title>Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis</brief_title>
  <official_title>Rectal Indomethacin to Prevent Post-ERCP Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether peri-procedural administration of rectal
      indomethacin, compared to placebo, can reduce the incidence of post-ERCP pancreatitis.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Futility
  </why_stopped>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Who Developed Acute Pancreatitis</measure>
    <time_frame>From randomization to 30 days after ERCP</time_frame>
    <description>Number of patients who developed pancreatitis following ERCP based on Atlanta Classification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Developed Severe Pancreatitis</measure>
    <time_frame>From randomization to 30 days after ERCP</time_frame>
    <description>Number of patients with severe acute pancreatitis based on the Atlanta Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Developed Moderately Severe Pancreatitis</measure>
    <time_frame>From randomization to 30 days after ERCP</time_frame>
    <description>Number of patients with moderately severe pancreatitis based on Atlanta Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Developed Mild Pancreatitis</measure>
    <time_frame>From randomization to 30 days after ERCP</time_frame>
    <description>Number of patient who developed mild acute pancreatitis based on the Atlanta Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Developed Gastrointestinal Bleeding</measure>
    <time_frame>From randomization to 30 days after ERCP</time_frame>
    <description>Number of patients who developed any type of gastrointestinal bleeding from time of ERCP to 30 days post procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patient Deaths</measure>
    <time_frame>From randomization to 30 days after ERCP</time_frame>
    <description>Number of patients who died from any cause from the time of ERCP until 30 days post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With 30 Days Hospital Re-admission</measure>
    <time_frame>From randomization until 30 days after ERCP</time_frame>
    <description>Number of patients admitted to the hospital for any cause following ERCP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">449</enrollment>
  <condition>Post-ERCP Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Indomethacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indomethacin 100 mg Per Rectum (PR) x 1 in peri-procedural period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo suppositories (#2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>100 mg Indomethacin PR x 1</description>
    <arm_group_label>Indomethacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Scheduled for an ERCP at Dartmouth-Hitchcock

          2. Age greater than 18 years old

          3. Ability to provide written informed consent

        Exclusion Criteria:

          1. Inability to provide written informed consent

          2. ERCP being performed for diagnosis and/or treatment of acute pancreatitis

          3. Current ongoing acute pancreatitis

          4. Previously documented allergy to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

          5. Contra-indication to NSAID therapy (creatinine level &gt;1.4 or active peptic ulcer
             disease), already taking NSAIDs (other than aspirin therapy for cardioprotection)

          6. Pregnant or nursing mothers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John M Levenick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Levenick JM, Gordon SR, Fadden LL, Levy LC, Rockacy MJ, Hyder SM, Lacy BE, Bensen SP, Parr DD, Gardner TB. Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients. Gastroenterology. 2016 Apr;150(4):911-7; quiz e19. doi: 10.1053/j.gastro.2015.12.040. Epub 2016 Jan 9.</citation>
    <PMID>26775631</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2013</study_first_submitted>
  <study_first_submitted_qc>January 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2013</study_first_posted>
  <results_first_submitted>July 29, 2016</results_first_submitted>
  <results_first_submitted_qc>July 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 20, 2016</results_first_posted>
  <last_update_submitted>September 28, 2016</last_update_submitted>
  <last_update_submitted_qc>September 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post ERCP acute pancreatitis</keyword>
  <keyword>Post Fine Needle Aspiration (FNA) acute pancreatitis</keyword>
  <keyword>Indomethacin</keyword>
  <keyword>Rectal Non Steroidal Anti-Inflammatory Drugs (NSAIDs)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All patients who presented to Dartmouth-Hitchcock Medical Center for Endoscopic Retrograde Cholangiopancreatography (ERCP) for any reason between March 2013 and December 2014</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Indomethacin</title>
          <description>Indomethacin 100 mg Per Rectum (PR) x 1 in peri-procedural period
Indomethacin: 100 mg Indomethacin PR x 1</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo suppositories (#2)
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="223"/>
                <participants group_id="P2" count="226"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="223"/>
                <participants group_id="P2" count="226"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patient randomized to receive rectal indomethacin or placebo</population>
      <group_list>
        <group group_id="B1">
          <title>Indomethacin</title>
          <description>Indomethacin 100 mg PR x 1 in peri-procedural period
Indomethacin: 100 mg Indomethacin PR x 1</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo suppositories (#2)
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="223"/>
            <count group_id="B2" value="226"/>
            <count group_id="B3" value="449"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.9" spread="23.7"/>
                    <measurement group_id="B2" value="64.3" spread="15.1"/>
                    <measurement group_id="B3" value="64.6" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Indication</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Acute Cholangitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Choledocholithiasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant Biliary Obstruction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biliary Stent Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biliary Leak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased Liver Tests/Jaundice</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreatic Stricture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suspected Sphincter of Oddi Dysfunction (SOD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreatic Leak/Disruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreatic Duct Stone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recurrent Acute Pancreatitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ampullectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of post-ERCP Pancreatitis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                    <measurement group_id="B2" value="217"/>
                    <measurement group_id="B3" value="431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Previous Sphincterotomy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous ERCP</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Difficult Cannulation</title>
          <description>Difficult Cannulation was defined by &gt;8 attempts at cannulation</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="184"/>
                    <measurement group_id="B3" value="361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Precut Biliary Sphincterotomy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="210"/>
                    <measurement group_id="B3" value="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Therapeutic Biliary Sphincterotomy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Therapeutic Pancreatic Sphincterotomy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                    <measurement group_id="B2" value="221"/>
                    <measurement group_id="B3" value="432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Minor Duct Sphincterotomy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="218"/>
                    <measurement group_id="B2" value="222"/>
                    <measurement group_id="B3" value="440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Balloon Dilation of Biliary Sphincter</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="206"/>
                    <measurement group_id="B3" value="408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Wire Cannulation of Pancreatic Duct</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pancreatography</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pancreatic Acinarization</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="218"/>
                    <measurement group_id="B2" value="222"/>
                    <measurement group_id="B3" value="440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Biliary Strent Placement</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pancreatic Stent Placement</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="191"/>
                    <measurement group_id="B3" value="378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Trainee Involvement</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concomitant Endoscopic Ultrasound with Fine Needle Aspiration (EUS/FNA)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Periprocedural Fluid Volume</title>
          <units>Milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="705" spread="335"/>
                    <measurement group_id="B2" value="703" spread="355"/>
                    <measurement group_id="B3" value="704" spread="345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who Developed Acute Pancreatitis</title>
        <description>Number of patients who developed pancreatitis following ERCP based on Atlanta Classification</description>
        <time_frame>From randomization to 30 days after ERCP</time_frame>
        <population>Patient who randomized into the study and received either rectal indomethacin or placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Indomethacin</title>
            <description>Indomethacin 100 mg PR x 1 in peri-procedural period
Indomethacin: 100 mg Indomethacin PR x 1</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suppositories (#2)
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Developed Acute Pancreatitis</title>
          <description>Number of patients who developed pancreatitis following ERCP based on Atlanta Classification</description>
          <population>Patient who randomized into the study and received either rectal indomethacin or placebo</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Developed Severe Pancreatitis</title>
        <description>Number of patients with severe acute pancreatitis based on the Atlanta Classification</description>
        <time_frame>From randomization to 30 days after ERCP</time_frame>
        <population>Assess the number of patients who developed severe acute pancreatitis</population>
        <group_list>
          <group group_id="O1">
            <title>Indomethacin</title>
            <description>Indomethacin 100 mg PR x 1 in peri-procedural period
Indomethacin: 100 mg Indomethacin PR x 1</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suppositories (#2)
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Developed Severe Pancreatitis</title>
          <description>Number of patients with severe acute pancreatitis based on the Atlanta Classification</description>
          <population>Assess the number of patients who developed severe acute pancreatitis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Developed Moderately Severe Pancreatitis</title>
        <description>Number of patients with moderately severe pancreatitis based on Atlanta Classification</description>
        <time_frame>From randomization to 30 days after ERCP</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Indomethacin</title>
            <description>Indomethacin 100 mg PR x 1 in peri-procedural period
Indomethacin: 100 mg Indomethacin PR x 1</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suppositories (#2)
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Developed Moderately Severe Pancreatitis</title>
          <description>Number of patients with moderately severe pancreatitis based on Atlanta Classification</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Developed Mild Pancreatitis</title>
        <description>Number of patient who developed mild acute pancreatitis based on the Atlanta Classification</description>
        <time_frame>From randomization to 30 days after ERCP</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Indomethacin</title>
            <description>Indomethacin 100 mg PR x 1 in peri-procedural period
Indomethacin: 100 mg Indomethacin PR x 1</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suppositories (#2)
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Developed Mild Pancreatitis</title>
          <description>Number of patient who developed mild acute pancreatitis based on the Atlanta Classification</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Developed Gastrointestinal Bleeding</title>
        <description>Number of patients who developed any type of gastrointestinal bleeding from time of ERCP to 30 days post procedure</description>
        <time_frame>From randomization to 30 days after ERCP</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Indomethacin</title>
            <description>Indomethacin 100 mg PR x 1 in peri-procedural period
Indomethacin: 100 mg Indomethacin PR x 1</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suppositories (#2)
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Developed Gastrointestinal Bleeding</title>
          <description>Number of patients who developed any type of gastrointestinal bleeding from time of ERCP to 30 days post procedure</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.75</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patient Deaths</title>
        <description>Number of patients who died from any cause from the time of ERCP until 30 days post-procedure</description>
        <time_frame>From randomization to 30 days after ERCP</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Indomethacin</title>
            <description>Indomethacin 100 mg PR x 1 in peri-procedural period
Indomethacin: 100 mg Indomethacin PR x 1</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suppositories (#2)
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patient Deaths</title>
          <description>Number of patients who died from any cause from the time of ERCP until 30 days post-procedure</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With 30 Days Hospital Re-admission</title>
        <description>Number of patients admitted to the hospital for any cause following ERCP</description>
        <time_frame>From randomization until 30 days after ERCP</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Indomethacin</title>
            <description>Indomethacin 100 mg PR x 1 in peri-procedural period
Indomethacin: 100 mg Indomethacin PR x 1</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suppositories (#2)
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With 30 Days Hospital Re-admission</title>
          <description>Number of patients admitted to the hospital for any cause following ERCP</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From randomization to 30 days after ERCP</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Indomethacin</title>
          <description>Indomethacin 100 mg PR x 1 in peri-procedural period
Indomethacin: 100 mg Indomethacin PR x 1</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo suppositories (#2)
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Severe Acute Pancreatitis Leading to Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Secondary Bacterial Peritonitis due to Multifocal Hepatocellular Carcinoma Leading to Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration Post-Procedure Leading to Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="223"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Bleeding</sub_title>
                <description>Patients with any type of gastrointestinal bleeding</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="223"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated due to indomethacin's lack of efficacy after 449 patients had been enrolled. Thus the study may be underpowered to draw conclusions about the role of indomethacin in preventing post ERCP pancreatitis</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>John M. Levenick</name_or_title>
      <organization>Penn State Hershey Medical Center/Dartmouth-Hitchcock Medical Center</organization>
      <phone>603-667-1332</phone>
      <email>jlevenick@hmc.psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

